JAZZ Jazz Pharmaceuticals plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JAZZ

Price (delayed)

$107.43

Market cap

$6.7B

P/E Ratio

16.4

Dividend/share

N/A

EPS

$6.55

Enterprise value

$10.96B

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
Jazz Pharmaceuticals's equity has increased by 21% YoY and by 7% from the previous quarter
The gross profit has grown by 9% YoY and by 3% from the previous quarter
Jazz Pharmaceuticals's quick ratio has increased by 8% from the previous quarter but it has decreased by 7% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: NVS TEVA PRGO SAGE

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
62.35M
Market cap
$6.7B
Enterprise value
$10.96B
Valuations
Price to earnings (P/E)
16.4
Price to book (P/B)
1.81
Price to sales (P/S)
1.77
EV/EBIT
18.76
EV/EBITDA
8.96
EV/Sales
2.86
Earnings
Revenue
$3.83B
EBIT
$584.36M
EBITDA
$1.22B
Free cash flow
$1.07B
Per share
EPS
$6.55
Free cash flow per share
$16.88
Book value per share
$59.36
Revenue per share
$60.58
TBVPS
$66.71
Balance sheet
Total assets
$11.39B
Total liabilities
$7.66B
Debt
$5.77B
Equity
$3.74B
Working capital
$1.9B
Liquidity
Debt to equity
1.54
Current ratio
2.24
Quick ratio
1.52
Net debt/EBITDA
3.49
Margins
EBITDA margin
31.9%
Gross margin
88.6%
Net margin
10.8%
Operating margin
15.1%
Efficiency
Return on assets
3.7%
Return on equity
11.8%
Return on invested capital
8.2%
Return on capital employed
5.9%
Return on sales
15.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-0.82%
1 week
-1.68%
1 month
-11.06%
1 year
-23.91%
YTD
-12.66%
QTD
-10.79%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$3.83B
Gross profit
$3.4B
Operating income
$578.58M
Net income
$414.83M
Gross margin
88.6%
Net margin
10.8%
JAZZ's operating margin has soared by 196% since the previous quarter
The gross profit has grown by 9% YoY and by 3% from the previous quarter
The revenue has grown by 4.8% YoY
Jazz Pharmaceuticals's gross margin has increased by 4% YoY

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
JAZZ P/E details
P/E
16.4
P/B
1.81
P/S
1.77
EV/EBIT
18.76
EV/EBITDA
8.96
EV/Sales
2.86
The price to book (P/B) is 28% lower than the 5-year quarterly average of 2.5 and 25% lower than the last 4 quarters average of 2.4
Jazz Pharmaceuticals's equity has increased by 21% YoY and by 7% from the previous quarter
The price to sales (P/S) is 41% less than the 5-year quarterly average of 3.0 and 20% less than the last 4 quarters average of 2.2
The revenue has grown by 4.8% YoY

Efficiency

How efficient is Jazz Pharmaceuticals business performance

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 49% greater than the total liabilities
The company's current ratio fell by 20% YoY but it rose by 9% QoQ
Jazz Pharmaceuticals's quick ratio has increased by 8% from the previous quarter but it has decreased by 7% YoY
The company's debt is 54% higher than its equity
Jazz Pharmaceuticals's equity has increased by 21% YoY and by 7% from the previous quarter
Jazz Pharmaceuticals's debt to equity has decreased by 18% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.